Summary
Boston Scientific Corporation (BSX) filed an 8-K on November 17, 2005, to report on the successful completion of a significant debt offering. The company issued $400 million in 5.50% Notes due 2015 and $350 million in 6.25% Notes due 2035, totaling $750 million in aggregate principal amount. This offering was conducted under the company's existing shelf registration statement, with J.P. Morgan Securities Inc., Deutsche Bank Securities Inc., and UBS Securities LLC acting as underwriters. The primary purpose for issuing these notes is to repay existing commercial paper borrowings and to fund general corporate purposes. This move indicates a strategic financial maneuver by Boston Scientific to strengthen its balance sheet, manage its debt obligations, and ensure liquidity for ongoing operations and potential future investments.
Key Highlights
- 1Completed a $750 million debt offering consisting of $400 million in 5.50% Notes due 2015 and $350 million in 6.25% Notes due 2035.
- 2The offering was executed under the company's existing shelf registration statement.
- 3Key underwriters included J.P. Morgan Securities Inc., Deutsche Bank Securities Inc., and UBS Securities LLC.
- 4Proceeds will be used to repay commercial paper borrowings.
- 5Remaining proceeds allocated for other general corporate purposes.
- 6The debt issuance demonstrates proactive capital management by Boston Scientific.
- 7The filing includes the Underwriting Agreement and forms of the Global Securities as exhibits.